Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 471

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 471
---
 31, 2024, this line includes a tax expense of € 58million ,

representing the estimated impact of Pillar Two based on Sanofi’s current understanding of Pillar Two rules.

(c) In determining the amount of the deferred tax liability for 2024 , 2023 and 2022 , Sanofi took into account changes in the ownership structure of certain

subsidiaries .

For the periods presented, the amount of deferred tax assets recognized in profit or loss that were initially subject to impairment

losses at the time of a business combination is immaterial.

D.31. Share of profit/loss from investments accounted for using the equity method The line item Share of profit/(loss) from investments accounted for using the equity method showed net income of € 60 million in 2024 (after charging an impairment loss of € 77 million on the equity-accounted investment in EUROAPI – see Note D.6.), compared with a net loss of € 136 million for 2023 and a net gain of € 55 million for 2022. Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. D.32. Net income attributable to non-controlling interests

The table below shows Net income attributable to non-controlling interests for the reporting periods presented:

| (€ million)                                                   | 2024 | 2023 | 2022 |
| Share of net income attributable to non-controlling interests |   58 |   36 |  113 |
| Total                                                         |   58 |   36 |  113 |

D.33. Related party transactions

The principal related parties are companies over which Sanofi has control or significant influence, joint ventures, key

management personnel, and principal shareholders.

Sanofi has not entered into any material transactions with any key management personnel. Financial relations with Sanofi’s

principal shareholders fall within the ordinary course of business and were immaterial in the years ended December 31, 2024 ,

2023 and 2022 .

Note F.1. lists the principal companies controlled by Sanofi; those companies are fully consolidated, as described in Note B.1.

Transactions between those companies, and between the parent company and its subsidiaries, are eliminated when preparing

the consolidated financial statements.

Transactions with companies over which Sanofi has significant influence, and with joint ventures, are presented in Note D.6.

Key management personnel include